Treatment of overdose in the synthetic opioid era
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Overdose deaths are often viewed as the leading edge of the opioid epidemic which has gripped the United States over the past two decades (Skolnick, 2018a). This emphasis is perhaps unsurprising because opioid overdose is both the number-one cause of death for individuals between 25 and 64 years old (Dezfulian et al., 2021) and a significant contributor to the decline in average lifespan (Dowell et al., 2017). Exacerbated by the COVID 19 pandemic, it was estimated there were 93,400 drug overdose deaths in the United States during the 12 months ending December 2020, with more than 69,000 (that is, >74%) of these fatalities attributed to opioid overdose (Ahmad et al., 2021). However, the focus on mortality statistics (Ahmad et al., 2021; Shover et al., 2020) tends to obscure the broader medical impact of nonfatal opioid overdose. Analyses of multiple databases indicate that for each opioid-induced fatality, there are between 6.4 and 8.4 non-fatal overdoses, exacting a significant burden on both the individual and society. Over the past 7-8 years, there has been an alarming increase in the misuse of synthetic opioids ("synthetics"), primarily fentanyl and related piperidine-based analogs. Within the past 2-3 years, a structurally unrelated class of high potency synthetics, benzimidazoles exemplified by etonitazene and isotonitazene ("iso"), have also appeared in illicit drug markets (Thompson, 2020; Ujvary et al. 2021). In 2020, it was estimated that over 80% of fatal opioid overdoses in the United States now involve synthetics (Ahmad et al., 2021). The unique physicochemical and pharmacological properties of synthetics described in this review are responsible for both the morbidity and mortality associated with their misuse as well as their widespread availability. This dramatic increase in the misuse of synthetics is often referred to as the "3rd wave" (Pardo et al., 2019; Volkow and Blanco, 2020) of the opioid epidemic. Among the consequences resulting from misuse of these potent opioids is the need for higher doses of the competitive antagonist, naloxone, to reverse an overdose. The development of more effective reversal agents such as those described in this review is an essential component of a tripartite strategy (Volkow and Collins, 2017) to reduce the biopsychosocial impact of opioid misuse in the "synthetic era".
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis
Ciccarone, D. (2021) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000717 · Cited by 987
Incidence, reversal, and prevention of opioid-induced respiratory depression
Dahan, A., Aarts, L., & Smith, T. W. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181c38c25 · Cited by 634 · cited 3×
“…cyclodextrin scaffolds that bind fentanyl and related molecules, antibody-based strategies that prevent opioids from entering the central nervous system) approaches have been proposed to treat opioid overdose (Dahan et al., 2010; France et al., 2021; Roozenkrans et al., 2014; Skolnick, 2018b).”
BackgroundMethodPark, T. W., Saitz, R., Ganoczy, D., Ilgen, M. A., & Bohnert, A. S. B. (2015) · BMJ · doi:10.1136/bmj.h2698 · Cited by 579
Holland, K. M., Jones, C., Vivolo-Kantor, A. M., Idaikkadar, N., Zwald, M., Hoots, B., Yard, E., D’Inverno, A., Swedo, E., Chen, M. S., et al. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.4402 · Cited by 578 · cited 1×
“These estimates do not fully capture the increase in opioid overdoses during the COVID-19 pandemic: there has been a 32% increase in opioid-related emergency department visits compared to pre-pandemic values (Holland et al., 2021).”
BackgroundBias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567 · cited 1×
“binding to MOR, and this has been hypothesized to contribute to its potency as a respiratory depressant relative to opiates like morphine (Schmid et al., 2017).”
BackgroundThe economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017
Florence, C., Luo, F., & Rice, K. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108350 · Cited by 511 · cited 1×
“Florence, Luo, and Rice (2021) have modelled the economic burden of opioid use disorder and fatal opioid overdose, estimated at $1.02 trillion in 2017.”
BackgroundInfluentialUniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs
Volpe, D. A., Tobin, G. A. M., Mellon, R. D., Katki, A. G., Parker, R. J., Colatsky, T., Kropp, T. J., & Verbois, S. L. (2011) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2010.12.007 · Cited by 446 · cited 3×
“…chemical space of this pharmacophore not fully a. Opioid(s) responsible for the overdose • Differences among opioids in af fi nities at MOR (e.g., Volpe et al., 2011; Burns et al., 2018), in activating post-receptor signaling pathways (He et al., 2021; Vandeputte et al., 2021) and in their…”
BackgroundThe Opioid Epidemic: Crisis and Solutions
Skolnick, P. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052534 · Cited by 307
Self-citationSaved by the nose: Bystander-administered intranasal naloxone hydrochloride for opioid overdose
Doe-Simkins, M., Walley, A. Y., Epstein, A., & Moyer, P. (2009) · American Journal of Public Health · doi:10.2105/ajph.2008.146647 · Cited by 250
Illicit fentanyls in the opioid street market: desired or imposed?
Mars, S. G., Rosenblum, D., & Ciccarone, D. (2019) · Addiction · doi:10.1111/add.14474 · Cited by 185 · cited 3×
“This initial fall can lead to a clinical impression that synthetics like fentanyl have a short half-life (Mars et al., 2019), but a complex pharmacokinetic pro-fi le with a plasma t 1/2 estimated in multiple clinical studies at 7 – 8 h (Ahonen et al., 2000; Holley & Van Steenis, 1988; Scott &…”
Background
Cited by
Old Drugs and New Challenges: A Narrative Review of Nitazenes
Pergolizzi Jr, J., Raffa, R., LeQuang, J. A. K., Breve, F., & Varrassi, G. (2023) · Cureus · doi:10.7759/cureus.40736 · Cited by 81
Clinical Pharmacokinetics and Pharmacodynamics of Naloxone
Saari, T. I., Strang, J., & Dale, O. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01355-6 · Cited by 77
Schumann, J. L., Syrjanen, R., Alford, K., Mashetty, S., Castle, J. W., Rotella, J., Maplesden, J., & Greene, S. L. (2023) · Journal of Analytical Toxicology · doi:10.1093/jat/bkac062 · Cited by 61
New Synthetic Opioids: Clinical Considerations and Dangers
Edinoff, A. N., Martinez Garza, D., Vining, S. P., Vasterling, M. E., Jackson, E. D., Murnane, K. S., Kaye, A. M., Fair, R. N., Torres, Y. J. L., Badr, A. E., et al. (2023) · Pain and Therapy · doi:10.1007/s40122-023-00481-6 · Cited by 61
Non-Fentanyl New Synthetic Opioids—An Update
Zawilska, J. B., Adamowicz, P., Kurpeta, M., & Wojcieszak, J. (2023) · Forensic Science International · doi:10.1016/j.forsciint.2023.111775 · Cited by 55
Metadata
- Authors
- Skolnick, P.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2022-05
- Volume
- 233
- Pages
- 108019
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W3205333294
- Cited by
- 120
- References
- 15
- FWCI
- 14.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of overdose in the synthetic opioid era. https://app.cochat.ai/papers/10.1016/j.pharmthera.2021.108019
- The paper
- Skolnick, P. (2022). Treatment of overdose in the synthetic opioid era. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2021.108019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.